Clinical Trial Update: An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating beloranib for efficacy, safety, and pharmacokinetics in individuals with Prader-Willi syndrome-associated obesity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Prader-willi Syndrome

Drugs mentioned

• Beloranib (Beloranib)

Snippet

Sponsor: Zafgen, Inc. | Conditions: Obesity, Over-weight | Phase 2 | Status: COMPLETED